University Medical Center of Southern Nevada | UMC Hospital, Clinical Trials Office

Research site

(Unclaimed)

Location

1800 W. Charleston Boulevard, Las Vegas, Nevada, United States of America

Site insights

Top conditions

Top treatments

Paclitaxel

Carboplatin

Cisplatin

Bevacizumab

Cyclophosphamide

Etoposide

Doxorubicin Hydrochloride

Lenalidomide

Dexamethasone

Fluorouracil

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 360 total trials

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

This phase II trial studies the side effects and how well nirogacestat works in treating patients less than 18 years of age with desmoid tumors that...

Active, not recruiting

Desmoid Fibromatosis

Unresectable Desmoid Fibromatosis

Procedure: Magnetic Resonance Imaging

Other: Quality-of-Life Assessment

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling

Acute Coronary Syndrome

Drug: Milvexian

Other: Placebo

Baroreflex Activation Therapy for Heart Failure (BeAT-HF)

The purpose of this clinical trial (NCT02627196) is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therap...

Active, not recruiting

Heart Failure

Device: BAROSTIM NEO® System

Drug: Medical Management

Benefits of µCor in Ambulatory Decompensated Heart Failure (BMADHF)

Subjects meeting the inclusion/exclusion criteria will wear the µCor for at least 90 days. During the study, clinic follow up will occur every 30 day...

Active, not recruiting

Heart Failure

Device: µCor

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of es...

Active, not recruiting

Breast Cancer

Drug: Letrozole

Other: Placebo

Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.

A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requ...

Enrolling

COVID-19 Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome

Drug: AV-001 Placebo Injection

Drug: AV-001 Injection

S0820, Adenoma and Second Primary Prevention Trial (PACES)

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and...

Active, not recruiting

Colorectal Neoplasms

Drug: eflornithine & sulindac placebo

Drug: Eflornithine placebo & sulindac placebo

Study of LAU-7b for the Treatment of COVID-19 Disease in Adults (RESOLUTION)

A randomized, double-blind, placebo-controlled Phase 2/3 Study of LAU-7b against confirmed COVID-19 Disease in hospitalized patients at a higher risk...

Active, not recruiting

COVID-19 Disease

Drug: Placebo oral capsule

Drug: LAU-7b

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in pa...

Enrolling

Prognostic Stage IA Breast Cancer AJCC v8

Prognostic Stage IB Breast Cancer AJCC v8

Other: Questionnaire Administration

Other: Quality-of-Life Assessment

Transanal Resection of Rectal Lesions With the ColubrisMX ELS System

This study is a prospective, single-arm, multi-center, open-label, staged clinical study.Overall Objective:1. To evaluate the safety and effectivenes...

Active, not recruiting

Rectal Lesion

Rectal Polyp

Device: ColubrisMX Endoluminal Surgical (ELS) System

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with me...

Enrolling

Recurrent Meningioma

NF2 Gene Mutation

Drug: Abemaciclib

Drug: Vismodegib